Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

On the Couch

On the Couch artwork

On the Couch with Jon Pilcher: What's Next for Neuren Pharma

Nov 12, 202434 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Welcome to another episode of 'On the Couch'. This occasional podcast series of chats with brokers, CEOs, and fund managers aims to give you an insight into the investing world. In this episode, Henry Jennings welcomes back Jon Pilcher, CEO of Neuren Pharma (NEU). Jon is an old friend, having joined us around two years ago to discuss the exciting deal with Acadia for their 'Daybue' drug, developed to treat Rett Syndrome. Since then, much has changed, with even more to come. 2025 is shaping up to be another good year for NEU. Cashed up with leverage to its new drug in trials, NNZ-2591. Don't miss this opportunity to hear the NEU success story first-hand. Disclaimer: This is general advice only and you should consult your financial adviser regarding any of the thoughts, ideas or insights in this podcast. Why not sign up for a free trial? Get access to expert insights and research and become a better investor.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. On the Couch with Dr Samantha South (ASX: PAB): Repurposing an Established Drug for Delirium

    Nov 20, 202629 minAudio

    In this episode of On the Couch, Henry Jennings speaks with Dr Samantha South, CEO of Patrys (ASX: PAB). Samantha explains delirium, an acute brain dysfunction that can cause confusion, agitation and hallucinations, and...

    Credit the people on this episode

  2. On the Couch with Ryan MacNeill (ASX: EQR): Why Tungsten Is in Focus at IMARC 2026

    Nov 20, 202616 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Ryan MacNeill, General Manager of Sales and Marketing at EQ Resources (ASX: EQR), at the International Mining and Resources Conference (IMARC) 2026....

    Credit the people on this episode

  3. On the Couch with Richard Morrow (ASX: LRT): Copper, Gold and Critical Minerals at IMARC 2026

    Nov 13, 202615 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Richard Morrow, Director of Lowell Resources Funds Management, at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir...

    Credit the people on this episode

  4. On the Couch with Jim McKerlie (ASX: IPT): From Explorer to Advanced Materials at IMARC 2026

    Nov 13, 202616 minAudio

    In this episode of On the Couch, Henry Jennings sits down with Jim McKerlie, Chairman of Impact Minerals (ASX: IPT), at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir podcast...

    Credit the people on this episode

  5. On the Couch with David Newling (ASX: AR1): Why Queensland Copper Is Consolidating at IMARC 2026

    Nov 11, 202611 minAudio

    In this episode of On the Couch, Henry Jennings speaks with David Newling, Chairman of Austral Resources (ASX: AR1), at the International Mining and Resources Conference (IMARC) 2026. Recorded live in the OnAir podcast...

    Credit the people on this episode